Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

About this update from Novocure Limited

[{"type":"text","content":"\nQuarterly net revenues of $133.6 million with 77% gross margin\n\nLast patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer\n\n ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division.\n\nThird quarter 2021 highlights include:\n\n\n\n \n\n\n\nThree Months Ended\nSeptember 30,\n\n\n\n \n\n\n\nNine Months Ended\nSeptember 30,\n\n\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n%\nChange\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n%\nChange\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nFinancial, in millions\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nNet revenues\n\n\n\n$\n\n\n\n133.6\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n132.7\n\n\n\n \n\n\n\n \n\n\n\n1\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n401.8\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n350.4\n\n\n\n \n\n\n\n \n\n\n\n15\n\n\n\n%\n\n\n\n\n\nGross Profit\n\n\n\n$\n\n\n\n103.4\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n104.3\n\n\n\n \n\n\n\n \n\n\n\n(1)\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n316.6\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n272.0\n\n\n\n \n\n\n\n \n\n\n\n16\n\n\n\n%\n\n\n\n\n\nNet income (loss)\n\n\n\n$\n\n\n\n(13.1)\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n9.3\n\n\n\n \n\n\n\n \n\n\n\n(241)\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n(31.9)\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n14.9\n\n\n\n \n\n\n\n \n\n\n\n(314)\n\n\n\n%\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nAdjusted EBITDA(1)\n\n\n\n$\n\n\n\n19.9\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n37.3\n\n\n\n \n\n\n\n \n\n\n\n(47)\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n59.2\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n80.4\n\n\n\n \n\n\n\n \n\n\n\n(26)\n\n\n\n%\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\...

More updates from Novocure Limited